Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.34 |
| ▸ | SYK | P43405 | 3/20 | 0.33 |
| ▸ | LYN | P07948 | 2/20 | 0.33 |
| ▸ | TXK | P42681 | 2/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | YES1 | P07947 | 1/20 | 0.33 |
| ▸ | FGR | P09769 | 1/20 | 0.33 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.33 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.33 |
| ▸ | CSK | P41240 | 1/20 | 0.33 |
| ▸ | BLK | P51451 | 1/20 | 0.33 |
| ▸ | BMX | P51813 | 1/20 | 0.33 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.33 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.33 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26113523 | 0.81 | MAPK14 (0.41) | MAPK14LCKSYKLYNTXK | |
| SCHEMBL30629799 | 0.81 | MAPK14 (0.41) | MAPK14LCKSYKLYNTXK | |
| SCHEMBL3631100 | 0.78 | MAPK14 (0.45) | MAPK14LCKSYKLYNTXK | |
| SCHEMBL4434790 | 0.76 | MAPK14 (0.43) | MAPK14LCKSYKLYNTXK | |
| SCHEMBL3634203 | 0.75 | EPHB4 (0.38) | CSKUSP14 | |
| SCHEMBL5388892 | 0.74 | MAPK14 (0.46) | MAPK14LCKSYK | |
| SCHEMBL3501205 | 0.74 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL3638254 | 0.72 | LCK (0.56) | MAPK14LCKP2RX7 | |
| SCHEMBL16061682 | 0.71 | CA12 (0.34) | CA12CA1CA2CA9CA14 | |
| SCHEMBL14840185 | 0.70 | SYK (0.37) | SYKCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150545-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | AstraZeneca AB (SE) | 2010-02-10 | — | — | EP | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| WO-2008132505-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | EPHB4, EPHB6, EPHB1 | MAPK14 864/4885LCK 504/4885SYK 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.